NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 246)
Posted On: 03/26/2019 4:06:35 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the update, the first tranche comprised of 7,500,000 common shares, each at a price of C$0.10, for gross proceeds of C$750,000. The closing of the second and final tranche of the offering is scheduled to occur in late March 2019. BriaCell intends to use net proceeds from the offering to finance its Phase IIa combination study of Bria-IMT(TM) with KEYTRUDA® by Merck & Co. Inc. (NYSE: MRK) in advanced breast cancer, as well as to pursue other research opportunities, for working capital and general corporate purposes. In addition, the company shared that it is finalizing analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT(TM), with pembrolizumab (KEYTRUDA®) in advanced breast cancer. BriaCell plans to announce this data via press release on April 3, 2019, concurrent with its poster presentation at the American Association for Cancer Research (“AACR”) Annual Meeting in Atlanta, Georgia.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the update, the first tranche comprised of 7,500,000 common shares, each at a price of C$0.10, for gross proceeds of C$750,000. The closing of the second and final tranche of the offering is scheduled to occur in late March 2019. BriaCell intends to use net proceeds from the offering to finance its Phase IIa combination study of Bria-IMT(TM) with KEYTRUDA® by Merck & Co. Inc. (NYSE: MRK) in advanced breast cancer, as well as to pursue other research opportunities, for working capital and general corporate purposes. In addition, the company shared that it is finalizing analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT(TM), with pembrolizumab (KEYTRUDA®) in advanced breast cancer. BriaCell plans to announce this data via press release on April 3, 2019, concurrent with its poster presentation at the American Association for Cancer Research (“AACR”) Annual Meeting in Atlanta, Georgia.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)